Table 7. Costs of moving current product candidates through the pipeline from their current phase.
Archetype | Preclinical
($, millions) |
Phase 1
($, millions) |
Phase 2
($, millions) |
Phase 3
($, millions) |
Total
($, millions) |
---|---|---|---|---|---|
Simple vaccine | 301.50 | 88.92 | 561.08 | 4930.42 | 5881.92 |
Complex vaccine | 83.00 | 22.62 | 132.35 | 912.93 | 1150.90 |
Unprecedented vaccine | 415.00 | 155.59 | 765.92 | 614.16 | 1950.67 |
Simple NCE | 106.60 | 53.76 | 189.18 | 906.47 | 1256.01 |
Complex NCE | 250.00 | 175.60 | 131.37 | 220.39 | 777.37 |
Simple repurposed drug | - | - | 185.60 | 469.93 | 655.53 |
Complex repurposed drug | 135.00 | 86.35 | 134.22 | 187.24 | 542.81 |
Simple biologic | 33.50 | 6.70 | 40.58 | 172.36 | 253.14 |
Complex biologic | 66.40 | 6.59 | 46.13 | 217.96 | 337.09 |
Concept &
Research |
Feasibility &
Planning |
Design &
Development |
Validation | ||
Diagnostic, assay
development |
6.00 | 26.76 | 91.33 | 180.82 | 304.91 |
Diagnostic, simple
platform development |
9.00 | 25.89 | 3025.46 | 100.31 | 3160.66 |
Other products | 6.00 | 8.82 | 13.63 | 35.81 | 64.27 |
Total | 1412.00 | 657.61 | 5316.86 | 8948.82 | 16335.29 |